Xylyx Bio Awarded $2.2M NIH SBIR Fast-Track Grant from National Heart, Lung, and Blood Institute
Award supports development of a pre-clinical compound testing platform to predict anti-fibrotic drug response
Xenogeneic cross-circulation is a promising method to recover marginal lungs. It may be more advantageous than EVLP but could introduce risks of zoonotic infections and sensitization to xenoantigens.